Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial.

Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, You YN, Maru DM, Munsell MF, Clemons MV, Kopetz SE, Garrett CR, Shureiqi I, Delclos ME, Krishnan S, Crane CH.

Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):301-5. doi: 10.1016/j.ijrobp.2013.10.034. Epub 2013 Dec 5.

2.

Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204.

Landry JC, Feng Y, Cohen SJ, Staley CA 3rd, Whittington R, Sigurdson ER, Nimeiri H, Verma U, Prabhu RS, Benson AB.

Cancer. 2013 Apr 15;119(8):1521-7. doi: 10.1002/cncr.27890. Epub 2013 Jan 3.

3.

Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer.

Blaszkowsky LS, Ryan DP, Szymonifka J, Borger DR, Zhu AX, Clark JW, Kwak EL, Mamon HJ, Allen JN, Vasudev E, Shellito PC, Cusack JC, Berger DL, Hong TS.

Ann Oncol. 2014 Jan;25(1):121-6. doi: 10.1093/annonc/mdt516.

4.

Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial.

Kennecke H, Berry S, Wong R, Zhou C, Tankel K, Easaw J, Rao S, Post J, Hay J.

Eur J Cancer. 2012 Jan;48(1):37-45. doi: 10.1016/j.ejca.2011.05.016. Epub 2011 Jun 12.

PMID:
21664123
5.

Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.

Kim SY, Hong YS, Kim DY, Kim TW, Kim JH, Im SA, Lee KS, Yun T, Jeong SY, Choi HS, Lim SB, Chang HJ, Jung KH.

Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):677-83. doi: 10.1016/j.ijrobp.2010.06.035. Epub 2010 Oct 1.

PMID:
20888703
6.

Neoadjuvant capecitabine, bevacizumab and radiotherapy for locally advanced rectal cancer: results of a single-institute Phase I study.

Miki Y, Maeda K, Hosono M, Nagahara H, Hirakawa K, Shimatani Y, Tsutsumi S, Miki Y.

J Radiat Res. 2014 Nov;55(6):1171-7. doi: 10.1093/jrr/rru063. Epub 2014 Aug 16.

7.

Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer.

Dellas K, Höhler T, Reese T, Würschmidt F, Engel E, Rödel C, Wagner W, Richter M, Arnold D, Dunst J.

Radiat Oncol. 2013 Apr 15;8:90. doi: 10.1186/1748-717X-8-90.

8.

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer.

Chadha AS, Skinner HD, Gunther JR, Munsell MF, Das P, Minsky BD, Delclos ME, Chatterjee D, Wang H, Clemons M, George G, Singh PK, Katz MH, Fleming JB, Javle MM, Wolff RA, Varadhachary GR, Crane CH, Krishnan S.

PLoS One. 2016 Jun 23;11(6):e0156910. doi: 10.1371/journal.pone.0156910. eCollection 2016.

9.

Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer.

Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, Wolff RA, Krishnan S, Hamilton S, Janjan NA, Maru DM, Ellis LM, Rodriguez-Bigas MA.

Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):824-30. doi: 10.1016/j.ijrobp.2009.02.037. Epub 2009 May 21.

PMID:
19464823
10.

Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.

Arbea L, Martínez-Monge R, Díaz-González JA, Moreno M, Rodríguez J, Hernández JL, Sola JJ, Ramos LI, Subtil JC, Nuñez J, Chopitea A, Cambeiro M, Gaztañaga M, García-Foncillas J, Aristu J.

Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):587-93. doi: 10.1016/j.ijrobp.2011.06.2008. Epub 2011 Nov 11.

PMID:
22079731
11.

Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.

Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG.

Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1367-75. doi: 10.1016/j.ijrobp.2011.05.027. Epub 2011 Jul 19.

12.

Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer.

van Dijk TH, Tamas K, Beukema JC, Beets GL, Gelderblom AJ, de Jong KP, Nagtegaal ID, Rutten HJ, van de Velde CJ, Wiggers T, Hospers GA, Havenga K.

Ann Oncol. 2013 Jul;24(7):1762-9. doi: 10.1093/annonc/mdt124. Epub 2013 Mar 22.

PMID:
23524865
13.

Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a Phase II study.

Koukourakis MI, Giatromanolaki A, Tsoutsou P, Lyratzopoulos N, Pitiakoudis M, Kouklakis G, Chloropoulou PA, Manolas K, Sivridis E.

Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):492-8. doi: 10.1016/j.ijrobp.2010.02.037. Epub 2010 Jun 30.

PMID:
20584585
14.

Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.

Jiang Y, Mackley HB, Kimchi ET, Zhu J, Gusani N, Kaifi J, Staveley-O'Carroll KF, Belani CP.

Cancer Chemother Pharmacol. 2014 Jul;74(1):205-10. doi: 10.1007/s00280-014-2488-7. Epub 2014 Jun 8.

PMID:
24908435
15.

Multicenter phase II clinical trial of preoperative capecitabine with concurrent radiotherapy in patients with locally advanced rectal cancer.

de las Heras M, Arias F, del Moral-Avila R, Gómez-Millán J, Jiménez E, Wals A, Tisaire JL, Alcantara MP.

Clin Transl Oncol. 2013 Apr;15(4):294-9. doi: 10.1007/s12094-012-0915-y. Epub 2012 Aug 2.

PMID:
22855196
16.
17.

Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study.

Velenik V, Ocvirk J, Music M, Bracko M, Anderluh F, Oblak I, Edhemovic I, Brecelj E, Kropivnik M, Omejc M.

Radiat Oncol. 2011 Aug 31;6:105. doi: 10.1186/1748-717X-6-105.

18.

Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer.

Jin T, Zhu Y, Luo JL, Zhou N, Li DC, Ju HX, Fan YT, Liu Y, Zhu YP, Feng HY, Liu LY.

Int J Colorectal Dis. 2015 Mar;30(3):337-45. doi: 10.1007/s00384-014-2097-2. Epub 2015 Jan 8.

PMID:
25564344
19.

Neoadjuvant-intensified treatment for rectal cancer: time to change?

Musio D, De Felice F, Bulzonetti N, Guarnaccia R, Caiazzo R, Bangrazi C, Raffetto N, Tombolini V.

World J Gastroenterol. 2013 May 28;19(20):3052-61. doi: 10.3748/wjg.v19.i20.3052.

20.

Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer.

Spigel DR, Bendell JC, McCleod M, Shipley DL, Arrowsmith E, Barnes EK, Infante JR, Burris HA 3rd, Greco FA, Hainsworth JD.

Clin Colorectal Cancer. 2012 Mar;11(1):45-52. doi: 10.1016/j.clcc.2011.04.002. Epub 2011 Aug 15.

PMID:
21840771

Supplemental Content

Support Center